Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes
The aim of this double-blind, parallel group study was to compare the effects of nebivolol and atenolol on blood pressure (BP) and insulin sensitivity in hypertensive patients with type II, non-insulin dependent diabetes mellitus (NIDDM). After a 4-week run-in period on placebo, 30 patients (14 male...
Gespeichert in:
| Veröffentlicht in: | Journal of human hypertension 1997-11, Vol.11 (11), p.753-757 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 757 |
|---|---|
| container_issue | 11 |
| container_start_page | 753 |
| container_title | Journal of human hypertension |
| container_volume | 11 |
| creator | FOGARI, R ZOPPI, A LAZZARI, P MUGELLINI, A LUSARDI, P PRETI, P VAN NUETEN, L VERTOMMEN, C |
| description | The aim of this double-blind, parallel group study was to compare the effects of nebivolol and atenolol on blood pressure (BP) and insulin sensitivity in hypertensive patients with type II, non-insulin dependent diabetes mellitus (NIDDM). After a 4-week run-in period on placebo, 30 patients (14 males and 16 females) aged 43 to 69 years, with stable NIDDM and mild to moderate hypertension (DBP > or =95 and |
| doi_str_mv | 10.1038/sj.jhh.1000533 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2640573791</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2640573791</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-d082edacd086147663222957db5eab6b897407750b04882962511c4af75af7ad3</originalsourceid><addsrcrecordid>eNo9kE1LxDAQhoMoun5cvQkBvXZN06Zpj7L4sSB40XNJ2imb0k1qJlX2D_i7za7FQ5hk3neeMC8h1ylbpiwr77Ff9ptNvDMmsuyILNJcFokQXB6TBasESyqeszNyjtgzthfLU3Ja5WlRlcWC_KzcdlReBfMFFLoOmoDUddSCNl9ucANVtqUqgD08nKV6cK6lowfEycNBNhanwViKYNFEkgm72KOb3Qg-7HuRjZPuD_BvEzY0RImu17Q1SkMAvCQnnRoQruZ6QT6eHt9XL8nr2_N69fCaNFkpQ9KykkOrmliL_SpFxjmvhGy1AKULXVYyZ1IKpllelrwquEjTJledFPGoNrsgt3_c0bvPCTDUvZu8jV_WvMiZkJms0uha_rka7xA9dPXozVb5XZ2yep96jX0dU6_n1OPAzYyd9Bbaf_scc9TvZl1ho4bOK9sY_LfxuBaTPPsFoxeNBg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2640573791</pqid></control><display><type>article</type><title>Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>FOGARI, R ; ZOPPI, A ; LAZZARI, P ; MUGELLINI, A ; LUSARDI, P ; PRETI, P ; VAN NUETEN, L ; VERTOMMEN, C</creator><creatorcontrib>FOGARI, R ; ZOPPI, A ; LAZZARI, P ; MUGELLINI, A ; LUSARDI, P ; PRETI, P ; VAN NUETEN, L ; VERTOMMEN, C</creatorcontrib><description>The aim of this double-blind, parallel group study was to compare the effects of nebivolol and atenolol on blood pressure (BP) and insulin sensitivity in hypertensive patients with type II, non-insulin dependent diabetes mellitus (NIDDM). After a 4-week run-in period on placebo, 30 patients (14 males and 16 females) aged 43 to 69 years, with stable NIDDM and mild to moderate hypertension (DBP > or =95 and <116 mm Hg) were randomised to receive either nebivolol 5 mg or atenolol 50 mg, both administered once daily for 6 months. At the end of the placebo and the active treatment periods, supine and standing BP was measured, 24-h urinary C-peptide, HbA1c, plasma glucose and lipid levels were evaluated and an euglycaemic hyperinsulinaemic clamp was performed to evaluate insulin sensitivity: glucose infusion rate during the last 60 min of clamp and total glucose requirements were evaluated. Nebivolol 5 mg once daily was of an equivalent efficacy as atenolol 50 mg once daily at reducing supine and standing systolic and diastolic BP values. Neither beta-blocker adversely affected carbohydrate metabolism in terms of insulin sensitivity, whole body glucose utilization, HbA1c and 24-h urinary C-peptide excretion. No significant changes in cholesterol (total, high density and low density lipoprotein) and triglycerides plasma levels were observed with both beta-blockers. These findings indicate that, in hypertensive patients with NIDDM, ie, in subjects who have established insulin resistance, treatment with nebivolol and atenolol neither further deteriorated insulin sensitivity nor adversely affected the lipid profile.</description><identifier>ISSN: 0950-9240</identifier><identifier>EISSN: 1476-5527</identifier><identifier>DOI: 10.1038/sj.jhh.1000533</identifier><identifier>PMID: 9416986</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing</publisher><subject>Adrenergic beta-Antagonists - adverse effects ; Adrenergic beta-Antagonists - therapeutic use ; Adult ; Aged ; Antihypertensive agents ; Antihypertensive Agents - adverse effects ; Antihypertensive Agents - therapeutic use ; Atenolol ; Atenolol - adverse effects ; Atenolol - therapeutic use ; Benzopyrans - adverse effects ; Benzopyrans - therapeutic use ; Biological and medical sciences ; Blood pressure ; Blood Pressure - drug effects ; Carbohydrate metabolism ; Cardiovascular system ; Cholesterol ; Diabetes ; Diabetes mellitus (insulin dependent) ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 ; Diabetic Angiopathies - drug therapy ; Diabetic Angiopathies - physiopathology ; Double-Blind Method ; Ethanolamines - adverse effects ; Ethanolamines - therapeutic use ; Female ; Glucose ; Glucose metabolism ; Humans ; Hypertension ; Hypertension - drug therapy ; Insulin ; Insulin Resistance ; Low density lipoprotein ; Male ; Medical sciences ; Middle Aged ; Nebivolol ; Patients ; Peptides ; Pharmacology. Drug treatments ; Placebos ; Plasma levels ; Sensitivity analysis ; Single-Blind Method ; Triglycerides</subject><ispartof>Journal of human hypertension, 1997-11, Vol.11 (11), p.753-757</ispartof><rights>1998 INIST-CNRS</rights><rights>Macmillan Publishers Limited 1997.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-d082edacd086147663222957db5eab6b897407750b04882962511c4af75af7ad3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2082072$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9416986$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FOGARI, R</creatorcontrib><creatorcontrib>ZOPPI, A</creatorcontrib><creatorcontrib>LAZZARI, P</creatorcontrib><creatorcontrib>MUGELLINI, A</creatorcontrib><creatorcontrib>LUSARDI, P</creatorcontrib><creatorcontrib>PRETI, P</creatorcontrib><creatorcontrib>VAN NUETEN, L</creatorcontrib><creatorcontrib>VERTOMMEN, C</creatorcontrib><title>Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes</title><title>Journal of human hypertension</title><addtitle>J Hum Hypertens</addtitle><description>The aim of this double-blind, parallel group study was to compare the effects of nebivolol and atenolol on blood pressure (BP) and insulin sensitivity in hypertensive patients with type II, non-insulin dependent diabetes mellitus (NIDDM). After a 4-week run-in period on placebo, 30 patients (14 males and 16 females) aged 43 to 69 years, with stable NIDDM and mild to moderate hypertension (DBP > or =95 and <116 mm Hg) were randomised to receive either nebivolol 5 mg or atenolol 50 mg, both administered once daily for 6 months. At the end of the placebo and the active treatment periods, supine and standing BP was measured, 24-h urinary C-peptide, HbA1c, plasma glucose and lipid levels were evaluated and an euglycaemic hyperinsulinaemic clamp was performed to evaluate insulin sensitivity: glucose infusion rate during the last 60 min of clamp and total glucose requirements were evaluated. Nebivolol 5 mg once daily was of an equivalent efficacy as atenolol 50 mg once daily at reducing supine and standing systolic and diastolic BP values. Neither beta-blocker adversely affected carbohydrate metabolism in terms of insulin sensitivity, whole body glucose utilization, HbA1c and 24-h urinary C-peptide excretion. No significant changes in cholesterol (total, high density and low density lipoprotein) and triglycerides plasma levels were observed with both beta-blockers. These findings indicate that, in hypertensive patients with NIDDM, ie, in subjects who have established insulin resistance, treatment with nebivolol and atenolol neither further deteriorated insulin sensitivity nor adversely affected the lipid profile.</description><subject>Adrenergic beta-Antagonists - adverse effects</subject><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Antihypertensive agents</subject><subject>Antihypertensive Agents - adverse effects</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Atenolol</subject><subject>Atenolol - adverse effects</subject><subject>Atenolol - therapeutic use</subject><subject>Benzopyrans - adverse effects</subject><subject>Benzopyrans - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood pressure</subject><subject>Blood Pressure - drug effects</subject><subject>Carbohydrate metabolism</subject><subject>Cardiovascular system</subject><subject>Cholesterol</subject><subject>Diabetes</subject><subject>Diabetes mellitus (insulin dependent)</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2</subject><subject>Diabetic Angiopathies - drug therapy</subject><subject>Diabetic Angiopathies - physiopathology</subject><subject>Double-Blind Method</subject><subject>Ethanolamines - adverse effects</subject><subject>Ethanolamines - therapeutic use</subject><subject>Female</subject><subject>Glucose</subject><subject>Glucose metabolism</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - drug therapy</subject><subject>Insulin</subject><subject>Insulin Resistance</subject><subject>Low density lipoprotein</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nebivolol</subject><subject>Patients</subject><subject>Peptides</subject><subject>Pharmacology. Drug treatments</subject><subject>Placebos</subject><subject>Plasma levels</subject><subject>Sensitivity analysis</subject><subject>Single-Blind Method</subject><subject>Triglycerides</subject><issn>0950-9240</issn><issn>1476-5527</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1LxDAQhoMoun5cvQkBvXZN06Zpj7L4sSB40XNJ2imb0k1qJlX2D_i7za7FQ5hk3neeMC8h1ylbpiwr77Ff9ptNvDMmsuyILNJcFokQXB6TBasESyqeszNyjtgzthfLU3Ja5WlRlcWC_KzcdlReBfMFFLoOmoDUddSCNl9ucANVtqUqgD08nKV6cK6lowfEycNBNhanwViKYNFEkgm72KOb3Qg-7HuRjZPuD_BvEzY0RImu17Q1SkMAvCQnnRoQruZ6QT6eHt9XL8nr2_N69fCaNFkpQ9KykkOrmliL_SpFxjmvhGy1AKULXVYyZ1IKpllelrwquEjTJledFPGoNrsgt3_c0bvPCTDUvZu8jV_WvMiZkJms0uha_rka7xA9dPXozVb5XZ2yep96jX0dU6_n1OPAzYyd9Bbaf_scc9TvZl1ho4bOK9sY_LfxuBaTPPsFoxeNBg</recordid><startdate>19971101</startdate><enddate>19971101</enddate><creator>FOGARI, R</creator><creator>ZOPPI, A</creator><creator>LAZZARI, P</creator><creator>MUGELLINI, A</creator><creator>LUSARDI, P</creator><creator>PRETI, P</creator><creator>VAN NUETEN, L</creator><creator>VERTOMMEN, C</creator><general>Nature Publishing</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>19971101</creationdate><title>Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes</title><author>FOGARI, R ; ZOPPI, A ; LAZZARI, P ; MUGELLINI, A ; LUSARDI, P ; PRETI, P ; VAN NUETEN, L ; VERTOMMEN, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-d082edacd086147663222957db5eab6b897407750b04882962511c4af75af7ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adrenergic beta-Antagonists - adverse effects</topic><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Antihypertensive agents</topic><topic>Antihypertensive Agents - adverse effects</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Atenolol</topic><topic>Atenolol - adverse effects</topic><topic>Atenolol - therapeutic use</topic><topic>Benzopyrans - adverse effects</topic><topic>Benzopyrans - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood pressure</topic><topic>Blood Pressure - drug effects</topic><topic>Carbohydrate metabolism</topic><topic>Cardiovascular system</topic><topic>Cholesterol</topic><topic>Diabetes</topic><topic>Diabetes mellitus (insulin dependent)</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2</topic><topic>Diabetic Angiopathies - drug therapy</topic><topic>Diabetic Angiopathies - physiopathology</topic><topic>Double-Blind Method</topic><topic>Ethanolamines - adverse effects</topic><topic>Ethanolamines - therapeutic use</topic><topic>Female</topic><topic>Glucose</topic><topic>Glucose metabolism</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - drug therapy</topic><topic>Insulin</topic><topic>Insulin Resistance</topic><topic>Low density lipoprotein</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nebivolol</topic><topic>Patients</topic><topic>Peptides</topic><topic>Pharmacology. Drug treatments</topic><topic>Placebos</topic><topic>Plasma levels</topic><topic>Sensitivity analysis</topic><topic>Single-Blind Method</topic><topic>Triglycerides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FOGARI, R</creatorcontrib><creatorcontrib>ZOPPI, A</creatorcontrib><creatorcontrib>LAZZARI, P</creatorcontrib><creatorcontrib>MUGELLINI, A</creatorcontrib><creatorcontrib>LUSARDI, P</creatorcontrib><creatorcontrib>PRETI, P</creatorcontrib><creatorcontrib>VAN NUETEN, L</creatorcontrib><creatorcontrib>VERTOMMEN, C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Journal of human hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FOGARI, R</au><au>ZOPPI, A</au><au>LAZZARI, P</au><au>MUGELLINI, A</au><au>LUSARDI, P</au><au>PRETI, P</au><au>VAN NUETEN, L</au><au>VERTOMMEN, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes</atitle><jtitle>Journal of human hypertension</jtitle><addtitle>J Hum Hypertens</addtitle><date>1997-11-01</date><risdate>1997</risdate><volume>11</volume><issue>11</issue><spage>753</spage><epage>757</epage><pages>753-757</pages><issn>0950-9240</issn><eissn>1476-5527</eissn><abstract>The aim of this double-blind, parallel group study was to compare the effects of nebivolol and atenolol on blood pressure (BP) and insulin sensitivity in hypertensive patients with type II, non-insulin dependent diabetes mellitus (NIDDM). After a 4-week run-in period on placebo, 30 patients (14 males and 16 females) aged 43 to 69 years, with stable NIDDM and mild to moderate hypertension (DBP > or =95 and <116 mm Hg) were randomised to receive either nebivolol 5 mg or atenolol 50 mg, both administered once daily for 6 months. At the end of the placebo and the active treatment periods, supine and standing BP was measured, 24-h urinary C-peptide, HbA1c, plasma glucose and lipid levels were evaluated and an euglycaemic hyperinsulinaemic clamp was performed to evaluate insulin sensitivity: glucose infusion rate during the last 60 min of clamp and total glucose requirements were evaluated. Nebivolol 5 mg once daily was of an equivalent efficacy as atenolol 50 mg once daily at reducing supine and standing systolic and diastolic BP values. Neither beta-blocker adversely affected carbohydrate metabolism in terms of insulin sensitivity, whole body glucose utilization, HbA1c and 24-h urinary C-peptide excretion. No significant changes in cholesterol (total, high density and low density lipoprotein) and triglycerides plasma levels were observed with both beta-blockers. These findings indicate that, in hypertensive patients with NIDDM, ie, in subjects who have established insulin resistance, treatment with nebivolol and atenolol neither further deteriorated insulin sensitivity nor adversely affected the lipid profile.</abstract><cop>Basingstoke</cop><pub>Nature Publishing</pub><pmid>9416986</pmid><doi>10.1038/sj.jhh.1000533</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-9240 |
| ispartof | Journal of human hypertension, 1997-11, Vol.11 (11), p.753-757 |
| issn | 0950-9240 1476-5527 |
| language | eng |
| recordid | cdi_proquest_journals_2640573791 |
| source | MEDLINE; SpringerLink Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Adrenergic beta-Antagonists - adverse effects Adrenergic beta-Antagonists - therapeutic use Adult Aged Antihypertensive agents Antihypertensive Agents - adverse effects Antihypertensive Agents - therapeutic use Atenolol Atenolol - adverse effects Atenolol - therapeutic use Benzopyrans - adverse effects Benzopyrans - therapeutic use Biological and medical sciences Blood pressure Blood Pressure - drug effects Carbohydrate metabolism Cardiovascular system Cholesterol Diabetes Diabetes mellitus (insulin dependent) Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 Diabetic Angiopathies - drug therapy Diabetic Angiopathies - physiopathology Double-Blind Method Ethanolamines - adverse effects Ethanolamines - therapeutic use Female Glucose Glucose metabolism Humans Hypertension Hypertension - drug therapy Insulin Insulin Resistance Low density lipoprotein Male Medical sciences Middle Aged Nebivolol Patients Peptides Pharmacology. Drug treatments Placebos Plasma levels Sensitivity analysis Single-Blind Method Triglycerides |
| title | Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T06%3A07%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20effects%20of%20nebivolol%20and%20atenolol%20on%20blood%20pressure%20and%20insulin%20sensitivity%20in%20hypertensive%20subjects%20with%20type%20II%20diabetes&rft.jtitle=Journal%20of%20human%20hypertension&rft.au=FOGARI,%20R&rft.date=1997-11-01&rft.volume=11&rft.issue=11&rft.spage=753&rft.epage=757&rft.pages=753-757&rft.issn=0950-9240&rft.eissn=1476-5527&rft_id=info:doi/10.1038/sj.jhh.1000533&rft_dat=%3Cproquest_cross%3E2640573791%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2640573791&rft_id=info:pmid/9416986&rfr_iscdi=true |